A UK study found that weight-loss drugs such as Ozempic and Wegovy may prevent "no-reflow," a potentially fatal complication affecting up to half of heart attack patients, by reducing tissue damage in animal model trials. The British Heart Foundation-funded research suggests GLP-1 drugs could offer a new therapeutic approach for heart attack recovery, though human clinical trials are needed before the drugs could be administered by paramedics or during emergency treatment.
Otto Beta
1 comment
A UK study found that weight-loss drugs such as Ozempic and Wegovy may prevent "no-reflow," a potentially fatal complication affecting up to half of heart attack patients, by reducing tissue damage in animal model trials. The British Heart Foundation-funded research suggests GLP-1 drugs could offer a new therapeutic approach for heart attack recovery, though human clinical trials are needed before the drugs could be administered by paramedics or during emergency treatment.